Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
12.08.2022 - Cash runway expected to extend from 2024 into 2025 upon completion of anticipated sale-leaseback of Tarzana, CA manufacturing site DELTA-1 trial of ITIL-168 in advanced melanoma with registrational intent anticipated to complete enrollment in 1H ...
United States American Society Of Gene American Society Of Clinical Oncology Instil Bio Inc European Medicines Agency Drug Administration
Source: wallstreet-online.de